Skip to Content

Generic Movantik Availability

Movantik is a brand name of naloxegol, approved by the FDA in the following formulation(s):

MOVANTIK (naloxegol oxalate - tablet;oral)

  • Manufacturer: ASTRAZENECA PHARMS
    Approval date: September 16, 2014
    Strength(s): EQ 12.5MG BASE, EQ 25MG BASE [RLD]

Has a generic version of Movantik been approved?

No. There is currently no therapeutically equivalent version of Movantik available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Movantik. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Polymer conjugates of opioid antagonists
    Patent 7,056,500
    Issued: June 6, 2006
    Inventor(s): Bentley; Michael David & Roberts; Michael James & Shen; Xiaoming & Cheng; Lin
    Assignee(s): Nektar Therapeutics AL, Corporation
    The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
    Patent expiration dates:
    • June 29, 2024
      ✓ 
      Patent use: TREATMENT OF OPIOID-INDUCED CONSTIPATION
      ✓ 
      Drug product
  • Polymer conjugates of opioid antagonists
    Patent 7,662,365
    Issued: February 16, 2010
    Inventor(s): Bentley; Michael David & Roberts; Michael James & Shen; Xiaoming & Cheng; Lin
    Assignee(s): Nektar Therapeutics
    The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
    Patent expiration dates:
    • October 18, 2022
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Chemically modified small molecules
    Patent 7,786,133
    Issued: August 31, 2010
    Inventor(s): Bentley; Michael D. & Viegas; Tacey X. & Goodin; Richard R. & Cheng; Lin & Zhao; Xuan
    Assignee(s): Nektar Therapeutics
    The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Patent expiration dates:
    • December 19, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Chemically modified small molecules
    Patent 8,067,431
    Issued: November 29, 2011
    Inventor(s): Fishburn; C. Simone & Lechuga-Ballesteros; David & Viegas; Tacey & Kuo; Mei-Chang & Song; Yuan & Gursahani; Hema & Leach; Chester
    Assignee(s): Nektar Therapeutics
    Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
    Patent expiration dates:
    • December 16, 2024
      ✓ 
      Patent use: TREATMENT OF OPIOID-INDUCED CONSTIPATION
  • Polymer conjugates of opioid antagonists
    Patent 8,617,530
    Issued: December 31, 2013
    Assignee(s): Nektar Therapeutics
    The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
    Patent expiration dates:
    • October 18, 2022
      ✓ 
      Patent use: TREATMENT OF OPIOID-INDUCED CONSTIPATION
  • Crystalline naloxol-peg conjugate
    Patent 9,012,469
    Issued: April 21, 2015
    Assignee(s): AstraZeneca AB Nektar Therapeutics
    Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.
    Patent expiration dates:
    • April 2, 2032
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 16, 2019 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide